帕金森氏症治疗药的全球市场 (2022-2028年):各药物类型 (脱羧酶抑制剂、多巴胺促效剂)、给药途径、流通管道的规模、占有率、成长分析、预测

Global Parkinson's Disease Drug Market Size, Share, Growth Analysis, By Drug Type(Decarboxylase Inhibitors, Dopamine Agonists), By Route of Administration, By Distribution Channel - Industry Forecast 2022-2028

出版日期: 2023年04月13日 | 出版商:

SkyQuest | 英文 165 Pages | 商品交期: 3-5个工作天内

价格

简介目录

帕金森氏症治疗药的市场规模，2021年是42亿8,000万美元，2022年是46亿1,000万美元，从2023年到2030年的预测期间中预计以12.1％的年复合成长率发展，2030年成长到119亿8,000万美元的规模。

由于疾病盛行率上升，为了管理症状需要长的期间，预计在预测期间内的市场成长。还有也由于脑移植的并用药的需求剧增，延长持续刺激多巴胺作动性神经元的药物的作用，基因治疗，政府的资金提供计划等各种要素而成长。

本报告提供全球帕金森氏症治疗药的市场调查，市场概要，市场的各种影响因素的分析，技术、革新趋势，市场规模的变化、预测，各种区分、各地区的明细，竞争情形，主要企业简介等彙整资讯。

市场动态
促进因素
机会
阻碍因素
课题
法规情形
SWOT分析
波特分析
未来阻碍相关Skyquest的特别洞察
全球帕金森氏症治疗药市场:各药物类型
脱羧酶抑製剂抑制剂(左旋多巴/碳度巴)
多巴胺促效剂
单胺氧化酶B型(MAO-B)抑制剂
儿茶酚-O-甲基转移酵素(COMT)抑制剂
全球帕金森氏症治疗药市场:各给药途径
口服
注射剂
经皮
全球帕金森氏症治疗药市场:各流通管道
医院药局
零售药局
线上药局

市场规模:各地区

北美
欧洲
亚太地区
南美
中东、非洲

主要企业简介

竞争情形
对像企业数
主要企业的地位
主要企业的市场占有率
Pfizer, Inc.
Impax Laboratories, Inc.
Hoffmann-La Roche Ltd
Novartis Ag
Merck &Co., Inc.
Orion Pharma
Teva Pharmaceutical Industries Ltd.
Boehringer Ingelheim GmbH
Acadia Pharmaceuticals Inc.
Vertical Pharmaceuticals, Llc
GlaxoSmithKline PLC
Acadia Pharmaceuticals Inc.
Dr. Reddy's Laboratories Ltd.
Wockhardt
Stada Arzneimittel Ag
Mylan NV
Cipla Inc.
Par Pharmaceutical
Daiichi Sankyo Company Ltd
Apotex Inc.

简介目录

Product Code: SQSG35I2024

Global Parkinson's Disease Drug Market size was valued at USD 4.28 billion in 2021 and is poised to grow from USD 4.61 billion in 2022 to USD 11.98 billion by 2030, growing at a CAGR of 12.1% in the forecast period (2023-2030).

Parkinson's disease is a neurological ailment that mostly affects the parts of the brain responsible for controlling movement, making it difficult to perform daily tasks. Parkinson's disease currently affects more than 10 million people worldwide. Tremors, stiffness, difficulty walking, and other symptoms are typically seen because of the decrease in dopamine production that results from it. Over the course of the forecast period, the Parkinson's disease drug market is anticipated to rise due to the rising prevalence of the condition and the lengthy time period needed to manage its symptoms. The market for Parkinson's disease is growing due to a variety of factors, including the surge in demand for combination medicines that promote brain transplantation, the extended effect of medications that constantly stimulate dopaminergic neurons, gene therapy, and government funding programmes.

The Parkinson's disease market is also benefited by the growing population, an improved healthcare system, research and development initiatives, and greater healthcare costs. Due to the patent expiration of branded medications and a strong drug pipeline, the Parkinson's disease market players are also anticipated to profit from profitable prospects for the duration of the projected time.

Top-down and bottom-up approaches were used to estimate and validate the size of global Parkinson's Disease Drug Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analysed to get the final quantitative and qualitative data.

Segments covered in this report

The Global Parkinson's Disease Drug Market is segmented based on drug type, route of administration, distribution channel, and region. Based on Drug Type, it is categorized into Decarboxylase Inhibitors (Levodopa/Carbidopa), Dopamine Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitors. Based on Route of Administration, it is categorized into Oral, Injection, and Transdermal. Based on Distribution Channel, it is categorized into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on region, it is categorized into North America, Europe, Asia Pacific, The Middle East and Africa, and Latin America.

Drivers

The ageing of the population and the rise in Parkinson's cases: Two significant factors influencing the growth of this market are the increasing ageing of the population and the incidence of neurological diseases. Parkinson's disease sufferers are becoming more numerous, which is driving up demand for the medications needed to treat the condition. Over the projected period, this is anticipated to boost the expansion of the global market for Parkinson's disease medications.

Restraints

It is anticipated that the market expansion will be constrained by the high cost of treating Parkinson's disease: Due to the high cost of treating Parkinson's disease, which is the primary factor impeding the market's growth throughout the forecast period, the financial burden of Parkinson's disease is growing on people, families, and the national government.

Market Trends

An increase in Parkinson's disease research and development: The increase in funding from governments and businesses for the study and development of Parkinson's disease pharmaceuticals is a significant trend in the market for Parkinson's therapies. Companies engaged in the drug development for this condition are working to create novel and cutting-edge treatments for the condition. As a result, growing investments in the creation of Parkinson's pharmaceuticals are anticipated to sustain the market for medications treating the condition.

Executive Summary

Market overview

Exhibit: Executive Summary - Chart on Market Overview
Exhibit: Executive Summary - Data Table on Market Overview
Exhibit: Executive Summary - Chart on Global Global Parkinson's Disease Drug Market Characteristics
Exhibit: Executive Summary - Chart on Market by Geography
Exhibit: Executive Summary - Chart on Market Segmentation
Exhibit: Executive Summary - Chart on Incremental Growth
Exhibit: Executive Summary - Data Table on Incremental Growth
Exhibit: Executive Summary - Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

Market Dynamics
Exhibit: Impact analysis of DROC, 2021
Drivers
Opportunities
Restraints
Challenges
SWOT Analysis

KEY MARKET INSIGHTS

Technology Analysis
(Exhibit: Data Table: Name of technology and details)
Pricing Analysis
(Exhibit: Data Table: Name of technology and pricing details)
Supply Chain Analysis
(Exhibit: Detailed Supply Chain Presentation)
Value Chain Analysis
(Exhibit: Detailed Value Chain Presentation)
Ecosystem Of the Market
Exhibit: Parent Market Ecosystem Market Analysis
Exhibit: Market Characteristics of Parent Market
IP Analysis
(Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
Trade Analysis
(Exhibit: Data Table: Import and Export data details)
Startup Analysis
(Exhibit: Data Table: Emerging startups details)
Raw Material Analysis
(Exhibit: Data Table: Mapping of key raw materials)
Innovation Matrix
(Exhibit: Positioning Matrix: Mapping of new and existing technologies)
Pipeline product Analysis
(Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
Macroeconomic Indicators

COVID IMPACT

Introduction
Impact On Economy-scenario Assessment
Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
Revised Market Size
Exhibit: Data Table on Global Global Parkinson's Disease Drug Market size and forecast 2021-2027 ($ million)
Impact Of COVID On Key Segments
Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
COVID Strategies By Company
Exhibit: Analysis on key strategies adopted by companies